aviscera bioscience  
AVISCERA BIOSCIENCE  
line decor
  HOME  ::  
line decor
   
 
Soluble Epoxide Hydrolase 2 (EPHX2)

Alternative name:

  • Cytosolic epoxide hydrolase (CEH)
  • Soluble epoxide hydrolase
  • EPHX2
This gene encodes a member of the epoxide hydrolase family. The protein, found in both the cytosol and peroxisomes, binds to specific epoxides and converts them to the corresponding dihydrodiols. Mutations in this gene have been associated with familial hypercholesterolemia.
We hypothesized that perinatal inhibition of soluble epoxide hydrolase (EPHX2), which metabolizes epoxyeicosatrienoic acids in the arachidonic acid (AA) cascade, with an orally active EPHX2 inhibitor, 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA), would persistently reduce blood pressure (BP) in adult SHR despite discontinuation of AUDA at 4wk of age. Renal Ephx2 gene expression was enhanced in SHR vs. WKY from 2d to 24wk. Effects of perinatal treatment with AUDA, supplied to SHR dams until 4wk after birth, on BP in female and male offspring and renal oxylipin metabolome in female offspring were observed and contrasted to female SHR for direct effects of AUDA (8-12wk). Briefly, inhibition of EPHX2 was effective in persistently reducing BP in female SHR when applied during the perinatal phase. This was accompanied by marked increases in major renal AA epoxides and decreases in renal lipoxygenase products of AA. Early inhibition of EPHX2 induced a delayed increase in renal 5-HETE at 24wk, in contrast to a decrease at 2wk. Inhibition of EPHX2 in female SHR from 8wk to 12wk did not reduce BP, but caused profound decreases in renal 15(S)-HETrE, LTB4, TBX2, 5-HETE and 20-HETE, and increases in TriHOMEs. In male SHR BP reduction after perinatal AUDA was transient. Thus, Ephx2 transcription and EPHX2 activity in early life may initiate mechanisms that eventually contribute to high BP in adult female SHR. However, programmed BP-lowering effects of perinatal EPHX2 inhibition in female SHR cannot be simply explained by persisting reduction in renal EPHX2 activity, but rather by more complex and temporally dynamic interactions between the renal EPHX2, lipoxygenase and cyclooxygenase pathways.
Koeners MP, , et al. Am J Physiol Endocrinol Metab. 2011 Jan 25. [Epub ahead of print]
 
Soluble epoxide hydrolase: a new target for cardioprotection
2MPG 2-mercaptopropionyl glycine, 5-HD 5-hydroxydecanoic acid, 14,15-EEZE 14,15-epoxyeicosa-5(Z)-enoic acid, AUDA .12-(3-adamantan-1-yt-ureido) dodecanoic acid, cPLA2 cytosolic phosphotipase A2, CYP Epox cytochrome P-450 epoxygenase, DHETs dihydroxyeicosatrienoic acids, mitoKATP mitochondrial ATP-sensitive potassium channel, mPTP mitochondrial permeabitity transitionpore, p-Akt phosphorylated Akt, p-GSK3β phospho-gtycogen synthase kinase-3β, Pl3K phosphoinositol-3-kinase, ROS reactive oxygen species, SarcKATP sarcolemmal ATP-sensitive potassium channel
Gross GJ, Nithipatikom K., et al. Curr Opin Investig Drugs. 2009 Mar;10(3):253-8.
Anti Human EPHX2 IgG
Code No.: A00142-01-100
Size: 100 ug
Price: $360.00 USD
Host: Rabbit
Antigen: human EPHX2 Rec.
Ab Type: Polyclonal IgG
Purification: Protein A
Applications: E, IHC
Working Dilution: 5 ug/ml)
Data Sheet: PDF
Human Soluble Epooxide Hydrolase 2 Recombinant
Code No.: 00142-01-100
Size: 100 ug
Price: $360.00 USD
Protein ID:P34913
Gene ID: 2053
MW:37 KD
Tag: His Tag on N-Terminus
Expressed: E. Coli
Purity: 90%
Data Sheet: PDF

 

Name
Code No.
Size
Price ($)
Soluble Epoxide Hydrolase 2 (Human) recombinant
00142-01-10
10 ug
80.00
Soluble Epoxide Hydrolase 2 (Human) recombinant
00142-01-50
50 ug
250.00
Soluble Epoxide Hydrolase 2 (Human) recombinant
100 ug
360.00
Soluble Epoxide Hydrolase 2 (Human) recombinant
00142-01-1000
1000 ug
3200.00
Rabbit Anti Soluble EPHX2(Human) IgG
100 ug
360.00